Merck’s KEYTRUDA Receives Positive EU CHMP Opinion for Bladder Cancer

Key Facts

1The EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending approval of KEYTRUDA.

In a move that strengthens the position of major pharmaceutical firms in the global oncology market, Merck announced that the EMA's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for KEYTRUDA. According to reports, the committee recommended the approval of the drug in combination with Padcev as a perioperative treatment for adults with resectable muscle-invasive bladder cancer. This recommendation is based on the therapy's potential as both a neoadjuvant and adjuvant treatment surrounding radical cystectomy.

This regulatory milestone arrives as healthcare stocks maintain steady performance, with Merck (MRK) shares closing at $147.17 on September 17, 2026, per market data. During that trading session, the stock reached a high of $147.65 and a low of $145.32. Such regulatory progress is a critical catalyst for the company, as a positive CHMP opinion typically precedes final European Commission approval, potentially expanding the market for its flagship oncology treatment.

Looking ahead, investors will monitor the final decision from the European Commission following this recommendation. With MRK priced at $147.17 (close September 17, 2026), market participants are also keeping an eye on broader economic indicators that could impact sector volatility. While the recent economic calendar shows significant inflation data from earlier in September, the focus for Merck remains on the successful commercial execution of its expanded oncology portfolio.